您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8353 处方药 7980 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国际免费电话:
QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 瑞士药房
产地国家: 瑞士
所属类别: 影响血液及造血系统药物->溶栓抗凝药物
处方药:处方药
包装规格: 5毫升/安瓿 20安瓿/盒
计价单位:
  点击放大  
生产厂家英文名:
Dirinco AG
该药品相关信息网址1:
https://www.citra-lock.com
原产地英文商品名:
Citra-Lock 4%, 5mL, 20 ampoules (Minimum Order: 30)
原产地英文药品名:
trisodium citrate
中文参考商品译名:
柠檬酸三钠溶液/注射剂 4%, 5 毫升, 20 安瓿 (最低订购量:30)
中文参考药品译名:
柠檬酸三钠溶液
原产地国家批准上市年份:
2000/08/25
英文适应病症1:
Anticoagulant for blood transfusion and blood storage
临床试验期:

中文适应病症参考翻译1:
输血、储血的抗凝剂
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(2018101418404430.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

中文名:柠檬酸三钠溶液

英文名:trisodium citrate

商品名:Citra-Lock 4%

成分:

•本品主要成份为:枸橼酸钠

药理作用:

•本品为输血、储血的抗凝剂。钙为凝血过程中必需物质,可促进凝血活素(凝血因子Ⅲ),凝血酶和纤维蛋白的形成,以及激活血小板释放凝血因子反应等。本品的枸椽酸根离子与血中钙离子生成难解离的可溶性络合物枸椽酸钙,此络合物易溶于水但不易解离,使血中钙离子减少,凝血过程受到抑制,从而阻止血液凝固。

枸椽酸钠一般在三羧酸循环中完全氧化代谢,其氧化速率接近正常的输血速度。本品作为体外抗凝剂,成人在600ml剂量下输血速度不很快且肝功正常时,不会产生不良反应。当输血速度太快或输血量过大时,因枸椽酸盐不能及时氧化,导致血钙过低,可出现枸椽酸中毒反应。

功能主治:

•本品用作输血、储血的抗凝剂。

•用法用量:

•输血时防止血凝,每100毫升全血中加入2.5%枸椽酸钠溶液10毫升,可使血液不再凝固。

不良反应:

•在正常输血速度下,本品不会出现不良反应,当输血速度太快或输血量太大(1000ml)以上时,受血者可因血钙过低和代谢性碱中毒而出现口唇发麻、手足抽搐,甚至出血倾向、血压下降,心室颤动或停搏。

注意事项:

•1.当肝肾功能不全或新生儿酶系统发育不全,不能充分代谢枸椽酸钠,即使缓慢输血也可能出现血钙过低现象,应特别注意。

2.为预防椽酸钠盐中毒反应,大量输血时可静脉注射适量葡萄糖酸钙或氯化钙。一般每输注1000毫升含枸椽酸钠血可静脉注射10%葡萄糖酸钙10毫升或5%氯化钙10毫升,以中和输入的大量枸椽酸钠,防止低钙血症发生。钙剂应单独注射,不能加入血液中,以免发生凝血。

Chinese name: Trisodium citrate solution

English name: trisodium citrate

Product Name: Citra-Lock 4%, 30%

Component:

•The main ingredient of this product is: sodium citrate

Pharmacological action:

• This product is an anticoagulant for blood transfusion and blood storage. Calcium is an essential substance in the blood coagulation process, which promotes the production of thromboplastin (coagulation factor III), thrombin and fibrin, and activates platelet release of clotting factor. The citrate ion of this product and the calcium ion in the blood form a soluble complex calcium citrate which is difficult to dissociate. This complex is easily soluble in water but not easily dissociated, which reduces the calcium ion in the blood and inhibits the blood coagulation process. To prevent blood from clotting.

Sodium citrate is generally completely oxidatively metabolized in the Krebs cycle, and its oxidation rate is close to the normal transfusion rate. As an in vitro anticoagulant, this product does not produce adverse reactions when the blood transfusion rate is not fast and the liver function is normal in 600ml. When the blood transfusion rate is too fast or the blood transfusion volume is too large, the citrate cannot be oxidized in time, resulting in hypocalcemia, and citrate poisoning reaction may occur.

Indications:

• This product is used as an anticoagulant for blood transfusion and blood storage.

•Usage and usage:

• Prevent blood clots during blood transfusion. Add 10 ml of 2.5% sodium citrate solution per 100 ml of whole blood to prevent blood from coagulating.

Adverse reactions:

• Under normal blood transfusion rate, this product will not have adverse reactions. When the blood transfusion rate is too fast or the blood transfusion volume is too high (1000ml) or more, the recipient may appear due to hypocalcemia and metabolic alkalosis. Lips and numbness, hand and foot convulsions, even bleeding tendency, blood pressure drop, ventricular fibrillation or arrest.

Note:

• 1. When liver and kidney dysfunction or neonatal enzyme system is incomplete, can not fully metabolize sodium citrate, even if blood transfusion may occur slowly, should pay special attention.

2. In order to prevent the sodium citrate salt poisoning reaction, a large amount of blood transfusion can be intravenously injected with an appropriate amount of calcium gluconate or calcium chloride. Generally, 1000 ml of sodium citrate-containing blood per infusion can be intravenously injected with 10 ml of 10% calcium gluconate or 10 ml of 5% calcium chloride to neutralize the input of a large amount of sodium citrate to prevent hypocalcemia. Calcium should be injected separately and should not be added to the blood to avoid blood clotting.


---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(2018101418404430.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2018-10-13
附件:
2018101418404430.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com